Home > Oncology > Blow to Roche’s cancer immunotherapy prospects as 2nd trial fails

Blow to Roche’s cancer immunotherapy prospects as 2nd trial fails

Reuters - 11/05/2022 - Development of a new cancer treatment pioneered by Roche was thrown into doubt on Wednesday when the immunotherapy drug failed to slow progression of lung cancer in a second trial, hitting the Swiss pharmaceutical maker's shares. In a study, a combination of the new drug tiragolumab and Roche's established Tecentriq drug did not slow disease progression in newly diagnosed cases of advanced non-small-cell lung cancer when compared with patients on Tecentriq only, the company said. That was after tiragolumab in March failed to slow progression of a different, more aggressive form of lung cancer. Analysts had given the second trial better odds of success. The setback could unsettle development efforts at more than half a dozen companies exploring similar compounds in a class of drugs called anti-TIGIT. Merck & Co is closely behind Roche in that race. Roche added that its trial would continue after the disappointing interim reado...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on